company background image
EQL logo

EQL Pharma OM:EQL Rapport sur les actions

Dernier prix

SEK 67.00

Capitalisation boursière

SEK 1.9b

7D

-1.2%

1Y

148.1%

Mise à jour

04 Nov, 2024

Données

Finances de l'entreprise +

EQL Pharma AB (publ)

OM:EQL Rapport sur les actions

Capitalisation boursière : SEK 1.9b

EQL Aperçu des actions

EQL Pharma AB (publ) développe, commercialise et vend des médicaments génériques aux pharmacies et aux hôpitaux en Suède, au Danemark, en Norvège, en Finlande et dans le reste de l'Europe.

A propos de l'entreprise

EQL analyse fondamentale
Score flocon de neige
Évaluation2/6
Croissance future6/6
Performances passées1/6
Santé financière3/6
Dividendes0/6

Récompenses

Trading at 56.6% below our estimate of its fair value
Earnings are forecast to grow 45.69% per year

Analyse des risques

Debt is not well covered by operating cash flow
High level of non-cash earnings

EQL Pharma AB (publ) Concurrents

Humana

OM:HUM

SEK 2.0b

Ambea

OM:AMBEA

SEK 7.7b

Stille

OM:STIL

SEK 1.9b

Dedicare

OM:DEDI

SEK 567.1m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour EQL Pharma
Historique des cours de bourse
Prix actuel de l'actionSEK 67.00
Plus haut sur 52 semainesSEK 69.00
Plus bas sur 52 semainesSEK 25.30
Bêta0.73
1Variation sur 1 mois15.52%
Variation sur 3 mois28.85%
Variation sur 1 an148.15%
3Variation sur 3 ans113.38%
Variation sur 5 ans407.58%
Évolution depuis l'introduction en bourse1,055.17%

Nouvelles et mises à jour récentes

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Recent updates

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Rendement pour les actionnaires

EQLSE HealthcareSE Marché
7D-1.2%-3.2%-2.3%
1Y148.1%43.2%21.0%

Rendement vs Industrie: EQL exceeded the Swedish Healthcare industry which returned 43.2% over the past year.

Rendement vs marché: EQL exceeded the Swedish Market which returned 21% over the past year.

Volatilité des prix

Is EQL's price volatile compared to industry and market?
EQL volatility
EQL Average Weekly Movement4.6%
Healthcare Industry Average Movement3.8%
Market Average Movement5.4%
10% most volatile stocks in SE Market10.8%
10% least volatile stocks in SE Market3.2%

Cours de l'action stable: EQL has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatilité au fil du temps: EQL's weekly volatility (5%) has been stable over the past year.

À propos de l'entreprise

FondéeSalariésPDGSite web
200622Axel Schorlingwww.eqlpharma.com

EQL Pharma AB (publ) développe, commercialise et vend des médicaments génériques aux pharmacies et aux hôpitaux en Suède, au Danemark, en Norvège, en Finlande et dans le reste de l'Europe. Elle propose des produits d'injection pour les soins hospitaliers et des formulations pour les soins ambulatoires. EQL Pharma AB (publ) a été constituée en 2006 et est basée à Lund, en Suède.

EQL Pharma AB (publ) Résumé des fondamentaux

Comment les bénéfices et les revenus de EQL Pharma se comparent-ils à sa capitalisation boursière ?
EQL statistiques fondamentales
Capitalisation boursièreSEK 1.95b
Bénéfices(TTM)SEK 26.29m
Recettes(TTM)SEK 290.75m

74.1x

Ratio P/E

6.7x

Ratio P/S

Le site EQL est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
EQL compte de résultat (TTM)
RecettesSEK 290.75m
Coût des recettesSEK 164.92m
Marge bruteSEK 125.84m
Autres dépensesSEK 99.54m
Les revenusSEK 26.29m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

Nov 06, 2024

Résultat par action (EPS)0.90
Marge brute43.28%
Marge bénéficiaire nette9.04%
Ratio dettes/capitaux propres74.7%

Quelles ont été les performances à long terme de EQL?

Voir les performances historiques et les comparaisons